Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Tojima

Showing results (61-70 of 62) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 62 results.
Acta Gastro-Enterologica Belgica|February 28, 2021
A change in the timing for starting systemic therapies for hepatocellular carcinoma: the comparison of sorafenib and lenvatinib as the first-line treatmentT Hatanaka, S Kakizaki, T Nagashima, et al.
Acta Gastro-Enterologica Belgica|February 28, 2021
Tolvaptan reduces the required amount of albumin infusion in patients with decompensated cirrhosis with uncontrolled ascites : a multicenter retrospective propensity score-matched cohort studyY Suzuki, A Naganuma, T Hoshino, et al.
Pageof 7

Showing results (61-70 of 62) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 62 results.
Acta Gastro-Enterologica Belgica|February 28, 2021
A change in the timing for starting systemic therapies for hepatocellular carcinoma: the comparison of sorafenib and lenvatinib as the first-line treatmentT Hatanaka, S Kakizaki, T Nagashima, et al.
Acta Gastro-Enterologica Belgica|February 28, 2021
Tolvaptan reduces the required amount of albumin infusion in patients with decompensated cirrhosis with uncontrolled ascites : a multicenter retrospective propensity score-matched cohort studyY Suzuki, A Naganuma, T Hoshino, et al.
Pageof 7